The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | CD38 and SLAMF7 targeting for multiple myeloma
Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, gives an overview of the monoclonal antibody treatment landscape in myeloma, highlighting the use of monoclonal antibodies targeting CD38 and SLAMF7. Elotuzumab, a SLAMF7-targeting monoclonal antibody, is approved for the treatment of myeloma in combination with lenalidomide or pomalidomide. Two CD38-targeting monoclonal antibodies are currently approved for the treatment of multiple myeloma: daratumumab and isatuximab. Dr Ocio gives an overview of these therapies, commenting on their mechanisms of action and discussing unanswered questions on their optimal usage. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Enrique M. Ocio, MD, PhD has received honoraria or consultancy fees from Janssen, BMS, Sanofi, GSK, Oncopeptides, Amgen, Takeda, Secura-Bio, MSD and Mundipharma-EDO.
